Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.56 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.56 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.41 |
| ▸ | PI4KA | P42356 | 1/20 | 0.41 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.41 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.41 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | XDH | P47989 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | CFTR | P13569 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26479837 | 0.83 | EGLN1 (0.55) | FGFR1EGLN1SRCHTT | |
| SCHEMBL17815600 | 0.81 | CFTR (0.54) | MKNK1MKNK2FGFR1EGLN1CFTR | |
| SCHEMBL5112478 | 0.78 | MAPT (0.47) | FGFR1EGLN1MAPTALDH1A1 | |
| SCHEMBL5108457 | 0.77 | MKNK1 (0.41) | MKNK1MKNK2FGFR1PI4KAPI4K2B | |
| SCHEMBL29623690 | 0.72 | MKNK1 (0.45) | MKNK1MKNK2FGFR1PI4KAPI4K2B | |
| SCHEMBL19350707 | 0.72 | MKNK1 (0.45) | MKNK1MKNK2FGFR1PI4KAPI4K2B | |
| SCHEMBL4790823 | 0.72 | RXFP1 (0.35) | ALDH1A1KDM4E | |
| SCHEMBL26479649 | 0.72 | CYP11B2 (0.37) | FGFR1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL6651640 | 0.72 | MKNK1 (1.00) | MKNK1MKNK2FGFR1PI4KAPI4K2B | |
| SCHEMBL31254392 | 0.70 | MAPT (0.45) | MKNK1MKNK2FGFR1PI4KAPI4K2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8609656-B2 | Heteroarylphenylurea derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2013-12-17 | — | — | US | disclosed |
| US-20080119466-A1 | Heteroarylphenylurea Derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-05-22 | — | — | US | disclosed |
| EP-1724258-A1 | HETEROARYLPHENYLUREA DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2006-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119466-A1 | Heteroarylphenylurea Derivative | CHRM1, CBR3, CHRM2 | MKNK1 4598/4885MKNK2 4276/4885FGFR1 982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.